Thus, the effects of alogliptin (and possibly other DPP4i) on liver function in type 2 diabetes and NAFLD may differ by PNPLA3 genotypes. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.